# Symphony Capital

Symphony Capital is an Asset Manager based in Dallas, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Dallas, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2002
- **Assets under management:** Undisclosed
- **Website:** symphonycapital.com
- **LinkedIn:** https://www.linkedin.com/company/symphony-capital

## About

Symphony Capital is an SEC-registered investment adviser in Dallas, TX. The firm manages approximately $10 million in regulatory assets. It has 4 employees and 3 investment advisers.

## Sectors

- Healthcare Services
- Digital Health

## People

- Mark Schwartz — Chairman
- Sundeep Arora — Managing Partner

## Questions

### Who runs investment decisions at Symphony Capital?

Mark Schwartz, the firm's founder and Chairman, sets the overall investment strategy and has led the firm since 2002. Sundeep Arora serves as Managing Partner and is involved in day-to-day deal origination and underwriting. Investment committees follow a structured-credit discipline, evaluating each drug royalty deal on actuarial cash-flow projections rather than equity-style growth metrics.

### How does Symphony Capital's royalty model differ from traditional biotech venture capital?

Symphony does not take equity stakes in portfolio companies. The firm provides non-dilutive capital through loans or synthetic royalty purchases that entitle it to a percentage of a specific drug's revenue for a defined period or until a target return is achieved. Returns are driven by actual prescription volumes and reimbursement rates — not exit valuations or stock appreciation — which historically produces low correlation to the Nasdaq Biotechnology Index.

### What investment stage does Symphony Capital typically target?

The firm targets commercial-stage and near-approval biotechnology and pharmaceutical assets where regulatory risk has been substantially reduced. Symphony generally avoids pre-clinical and Phase 1 clinical-stage companies, focusing instead on drugs that are already approved by the FDA or EMA and generating revenue, or those in late Phase 3 trials with a clear path to market.

### Which sectors does Symphony Capital explicitly avoid?

The firm avoids early-stage, pre-revenue biotechnology, as binary clinical-trial risk is incompatible with its cash-flow underwriting model. Symphony also does not invest in medical-device companies, healthcare IT, or healthcare services broadly defined — its mandate is deliberately narrow, confined to pharmaceutical and biologic drug royalty streams.

### What is Symphony Capital's known posture on co-investments alongside external GPs?

Symphony does not syndicate deals or participate in rounds led by external general partners. Because each transaction is a privately negotiated royalty or credit instrument tied to a specific drug's revenue stream, the firm controls its own origination and structuring in-house. Co-investment vehicles are limited to Symphony's own limited partners on select oversubscribed deals.

## Related profiles

- [Shangchuang Junqiang Investment Management](https://altss.com/profile/shangchuang-junqiang-investment-management)
- [Turim Family Office](https://altss.com/profile/turim-family-office)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/symphony-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology